NYSE · INSP
Healthcare · Medical - Devices
$68.10
Down-$3.08 (-4.33%)
Updated Oct 31, 2026, 6:00 PM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · INSP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
INSP closed at $68.10 after 21 trading sessions, down 2.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $70.63 | $71.195 | $67.80 | $68.10 | 796.4K |
| Oct 29, 2026 | $71.85 | $71.85 | $70.54 | $71.18 | 512.57K |
| Oct 28, 2026 | $71.25 | $71.99 | $70.15 | $70.97 | 367.1K |
| Oct 27, 2026 | $71.16 | $71.59 | $69.32 | $71.30 | 667.72K |
| Oct 26, 2026 | $70.51 | $72.40 | $70.00 | $71.01 | 528.47K |
| Oct 23, 2026 | $72.25 | $72.75 | $68.4391 | $71.11 | 592.14K |
| Oct 22, 2026 | $70.50 | $73.29 | $70.50 | $72.66 | 659.84K |
| Oct 21, 2026 | $70.84 | $72.50 | $70.40 | $71.07 | 554.25K |
| Oct 20, 2026 | $71.01 | $71.90 | $70.00 | $71.34 | 1.05M |
| Oct 19, 2026 | $68.73 | $70.28 | $68.44 | $70.15 | 656.15K |
| Oct 16, 2026 | $70.40 | $71.25 | $68.54 | $68.79 | 494.54K |
| Oct 15, 2026 | $68.72 | $70.40 | $68.33 | $70.12 | 621.18K |
| Oct 14, 2026 | $69.33 | $69.57 | $67.41 | $68.07 | 855.15K |
| Oct 13, 2026 | $71.37 | $72.46 | $68.62 | $68.86 | 1.04M |
| Oct 12, 2026 | $69.99 | $72.01 | $69.41 | $71.49 | 1.01M |
| Oct 9, 2026 | $67.20 | $69.73 | $66.83 | $68.89 | 867.34K |
| Oct 8, 2026 | $67.12 | $68.00 | $66.07 | $66.69 | 846.71K |
| Oct 7, 2026 | $67.13 | $68.37 | $66.50 | $67.45 | 1.48M |
| Oct 6, 2026 | $71.23 | $71.86 | $67.99 | $68.20 | 869.55K |
| Oct 5, 2026 | $69.66 | $71.36 | $68.6731 | $70.75 | 632.11K |
| Oct 2, 2026 | $71.74 | $71.74 | $68.44 | $69.97 | 761.93K |
The latest Smart Investors Daily articles mentioning INSP.
Company
Market Activity
Research & News
INSP research
Company profile and research snapshot.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Truist Securities | Hold | — |
| Oct 7, 2026 | Barclays | Underweight | — |
| Oct 2, 2026 | Freedom Capital Markets | Buy | — |
| Oct 1, 2026 | RBC Capital | Sector Perform | — |
| Sep 21, 2026 | Freedom Capital Markets | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
Yahoo · Oct 19, 2026
TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
Benzinga · Oct 14, 2026
Truist Securities analyst Richard Newitter maintains Inspire Medical Systems (NYSE:INSP) with a Hold and raises the price target from $62 to $78.
Yahoo · Oct 12, 2026
BURLINGTON, Mass., October 12, 2026--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine ("Katie") McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INSP.
